CAS: 1004-17-7; 2-Methyl-4-Pyrimidinecarboxaldehyde

该化合物是一种有机化合物,其特点是其火水环结构,这是一个六人组成的芳香环,含有1号站点和3号站点的两个氮原子. 该化合物的特征是2号站点的甲基组和4号站点的甲酰胺功能组,有助于其在有机合成中进行反应和潜在应用.该物质一般没有色素,可粉黄黄色液体或固体,视温度和纯度而定.由于可能具有毒性和再活性,因此在合成各种药物和农用化学品时,甲酰胺组的存在使它成为有用的中间体.此外,2-甲基乙基-4-丙氨基氨酯可能会展示生物活动,使其对医药化学感兴趣.其在极地溶剂中的溶解性和中等波动性是实验室环境中处理和应用该化合物的重要特征.在与许多有机化学品打交道时,应注意安全防范措施,因为可能具有毒性和再活性.

英文名称2-Methyl-4-Pyrimidinecarboxaldehyde
中文名称2-甲基-4-醛基嘧啶
IUPAC名称2-methylpyrimidine-4-carbaldehyde
其它别名2-甲基-4-嘧啶甲醛; 2-Methylpyrimidine-4-Carboxaldehyde; 4-Formyl-2-Methylpyrimidine; 4-Pyrimidinecarboxaldehyde, 2-Methyl- (7Ci,8Ci,9Ci)
CAS编号1004-17-7
MFCD编号:MFCD09832936
EINECS号:859-101-0
分子式:C6H6N2O分子量:122.13
产品CID: 9734
产品分类有机原料→分子砌块→芳杂环类化合物→嘧啶类化合物

相似结构搜索
InChIKey: BXHGNAADUUXBKK-UHFFFAOYSA-N
InChI=1S/C6H6N2O/c1-5-7-3-2-6(4-9)8-5/h2-4H,1H3
计算化学: 氢键受体数3.0氢键供体数*可旋转键数1.0

相似化合物

64571-34-2 1131605-06-5 73955-55-2

MSDS等安全信息

GHS符号GHS07
危险类别急性毒性类别4(经口)
特定目标器官毒性 - 单次接触类别3
皮肤腐蚀/刺激类别2
严重眼刺激类别2A
警示词Warning
危险描述H302 |吞咽有害.
H335 |可能引起呼吸道刺激.
H315 |造成皮肤刺激.
H319 |造成严重眼刺激.
防范说明P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
危险品标志Xi

欧盟法规

C&L通报

上下游产品

CAS号175277-33-5 4-二甲氧甲基-2-甲基嘧啶

合成工艺路线路线简述

合成目标产物 2-Methylpyrimidine-4-Carboxaldehyde 主要起始原料 4-(Dimethoxymethyl)-2-Methylpyrimidine
(文献来源)合成步骤主要原料 4-(Dimethoxymethyl)-2-Methylpyrimidine

📜4-二甲氧甲基-2-甲基嘧啶置于水,氢溴酸体系中,用水用作溶剂,化学反应 2.0H,反应生成2-甲基-4-嘧啶甲醛
参考文献: Pyrimidinylpyrazoles As Tgf-Beta Inhibitors[fr] Pyrimidinylpyrazoles Utilises Comme Inhibiteurs De Tgf-Beta
标题: Pyrimidinylpyrazoles As Tgf-Beta Inhibitors[fr] Pyrimidinylpyrazoles Utilises Comme Inhibiteurs De Tgf-Beta
摘要:这项发明是基于发现,式(I)的化合物具有与alk 5和/或alk 4的高亲和力,并可用作其拮抗剂,用于预防和/或治疗包括纤维化疾病在内的许多疾病.该发明涉及式(I)的化合物及其用途:式(I).

专利信息

专利号:US-6410526-B1
优先权日:1999-06-02
标题 :Î±v integrin receptor antagonists
发明人：DUGGAN MARK E; HARTMAN GEORGE D; MEISSNER ROBERT S; PERKINS JAMES J
权利人:MERCK & CO INC
摘要:The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as alphav integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors alphavbeta3 and alphavbeta5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

专利号:US-7056909-B2
优先权日:2000-07-26
标题 :Alpha v integrin receptor antagonists
发明人：WANG JIABING
权利人:MERCK & CO INC
摘要:The present invention relates to novel chain-fluorinated alkanoic acid derivatives thereof, their synthesis, and their use as Î±v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors Î±vÎ²3 and/or Î±vÎ²5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.